These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 28877839)

  • 21. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
    Growkova K; Kufová Z; Sevcikova T; Filipová J; Kascak M; Jelínek T; Grosicki S; Barchnicka A; Roziaková Ľ; Mistrík M; Simicek M; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):81-91. PubMed ID: 28903575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-free DNA analysis for detection of MYD88
    Demos MG; Hunter ZR; Xu L; Tsakmaklis N; Kofides A; Munshi M; Liu X; Guerrera ML; Leventoff CR; White TP; Flynn CA; Meid K; Patterson CJ; Yang G; Branagan AR; Sarosiek S; Castillo JJ; Treon SP; Gustine JN
    Am J Hematol; 2021 Jul; 96(7):E250-E253. PubMed ID: 33819355
    [No Abstract]   [Full Text] [Related]  

  • 24. Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar.
    Awata-Shiraiwa M; Yokohama A; Kanai Y; Gotoh N; Kasamatsu T; Handa H; Saitoh T; Murakami H; Hirato J; Ikota H; Tsukamoto N
    Acta Haematol; 2023; 146(5):384-390. PubMed ID: 36917966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
    King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
    Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
    Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
    Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
    Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
    Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
    Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
    Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Xu L; Hunter ZR; Yang G; Cao Y; Liu X; Manning R; Tripsas C; Chen J; Patterson CJ; Kluk M; Kanan S; Castillo J; Lindeman N; Treon SP
    Leukemia; 2014 Aug; 28(8):1698-704. PubMed ID: 24509637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
    Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
    J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88
    Guérémy A; Boucraut J; Boudjarane J; Grapperon AM; Fortanier E; Farnault L; Gabert J; Vely F; Lacroix R; Kouton L; Attarian S; Delmont E
    J Neurol; 2024 Mar; 271(3):1320-1330. PubMed ID: 37979093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
    Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
    J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
    Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
    J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waldenstrom macroglobulinemia: genetics dictates clinical course.
    Lenz G
    Blood; 2014 May; 123(18):2750-1. PubMed ID: 24786453
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Yu X; Li W; Deng Q; Li L; Hsi ED; Young KH; Zhang M; Li Y
    Cancer Res; 2018 May; 78(10):2457-2462. PubMed ID: 29703722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].
    Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.